Compounds > malabaricone b
Page last updated: 2024-11-08

malabaricone b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

malabaricone B: from maize (Myristica fragrans); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163001
CHEMBL ID489354
MeSH IDM0194848

Synonyms (20)

Synonym
nsc630196
nsc-630196
1-(2,6-dihydroxyphenyl)-9-(4-hydroxyphenyl)-1-nonanone
1-(2,6-dihydroxyphenyl)-9-(4-hydroxyphenyl)nonan-1-one
63335-24-0
nsc-287967
malabaricone b
nsc287967
1-nonanone, 1-(2,6-dihydroxyphenyl)-9-(4-hydroxyphenyl)-
bdbm50182486
CHEMBL489354
nsc 287967
malabaricon-b
DTXSID80212720
MS-25245
XM172957
E88737
CS-0145502
HY-N8517
AKOS040763674
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pancreatic alpha-amylaseSus scrofa (pig)IC50 (µMol)12.89001.35304.31088.9300AID1497070
AlbuminBos taurus (cattle)IC50 (µMol)40.34003.00003.00003.0000AID1497073
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)1.84000.00000.933210.0000AID1308877
AcetylcholinesteraseHomo sapiens (human)Ki4.33000.00001.27869.7300AID1308872
Sialidase AStreptococcus pneumoniaeIC50 (µMol)0.40000.30005.050010.0000AID1467530
Sialidase AStreptococcus pneumoniaeKi0.50000.10002.92839.4000AID1467535
CholinesteraseEquus caballus (horse)IC50 (µMol)1.76000.00002.22149.4000AID1308869
CholinesteraseEquus caballus (horse)Ki0.56000.00203.45989.3700AID1308873
Phosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)IC50 (µMol)2.75001.50002.57144.0000AID1600503; AID1600505
Phosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)IC50 (µMol)1.75001.00001.78574.0000AID1600504; AID1600506
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminBos taurus (cattle)
negative regulation of mitochondrial depolarizationAlbuminBos taurus (cattle)
cellular response to calcium ion starvationAlbuminBos taurus (cattle)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
ceramide biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
sphingomyelin biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
apoptotic processPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
sphingolipid biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathwayPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
ceramide biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
sphingomyelin biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
sphingolipid biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
regulation of bone mineralizationPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
ceramide phosphoethanolamine biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
ceramide biosynthetic processPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminBos taurus (cattle)
DNA bindingAlbuminBos taurus (cattle)
fatty acid bindingAlbuminBos taurus (cattle)
protein bindingAlbuminBos taurus (cattle)
toxic substance bindingAlbuminBos taurus (cattle)
pyridoxal phosphate bindingAlbuminBos taurus (cattle)
metal ion bindingAlbuminBos taurus (cattle)
enterobactin bindingAlbuminBos taurus (cattle)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
ceramide phosphoethanolamine synthase activityPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
kinase activityPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
sphingomyelin synthase activityPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
ceramide cholinephosphotransferase activityPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
ceramide phosphoethanolamine synthase activityPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
protein bindingPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
kinase activityPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
sphingomyelin synthase activityPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
ceramide cholinephosphotransferase activityPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminBos taurus (cattle)
extracellular spaceAlbuminBos taurus (cattle)
protein-containing complexAlbuminBos taurus (cattle)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
Golgi trans cisternaPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
Golgi membranePhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
nucleusPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
endoplasmic reticulumPhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
plasma membranePhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
membranePhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
plasma membranePhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
endoplasmic reticulum membranePhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
Golgi membranePhosphatidylcholine:ceramide cholinephosphotransferase 1 Homo sapiens (human)
Golgi membranePhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
nucleoplasmPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
Golgi apparatusPhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
plasma membranePhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
Golgi membranePhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
endoplasmic reticulum membranePhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
plasma membranePhosphatidylcholine:ceramide cholinephosphotransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1600506Noncompetitive inhibition of SMS2 (unknown origin) stably expressed in mouse ZS cells using 5 to 50 uM C6-NBD-ceramide as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by HPLC analysis2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
Malabaricone C as Natural Sphingomyelin Synthase Inhibitor against Diet-Induced Obesity and Its Lipid Metabolism in Mice.
AID337754Antimicrobial activity against Candida albicans ATCC 12301 after 24 hrs by agar dilution method
AID1308875Inhibition of equine serum BChE at 100 ug/ml using S-butyrylthiocholine chloride as substrate incubated for 30 mins by Ellman's microplate assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID1308874Inhibition of AChE (unknown origin) at 100 ug/ml using acetylthiocholine iodide as substrate incubated for 30 mins by Ellman's microplate assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID337758Antimicrobial activity against Candida albicans 3153 after 48 hrs by agar dilution method
AID1497073Antiglycation activity in bovine serum albumin assessed as inhibition of advanced glycated end product formation after 24 hrs in presence of alpha-D-glucose by fluorescence assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID1467530Inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1497076Antidiabetic activity in rat L6 cells assessed as effect on 2-NBDG uptake at 25 uM pretreated for 24 hrs followed by 2-NBDG addition after 30 mins by FACS (Rvb = 20%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID1308873Mixed inhibition of equine serum BChE using S-butyrylthiocholine chloride as substrate incubated for 30 mins by Lineweaver-Burk plot analysis2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID1467533Inhibition of Streptococcus pneumoniae sialidase NanC using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID515724Induction of Escherichia coli pBR322 DNA cleavage assessed as open circular form of DNA at 25 uM after 45 mins by agarose gel electrophoresis in presence of copper2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Comparative nuclease and anti-cancer properties of the naturally occurring malabaricones.
AID1600504Inhibition of SMS2 (unknown origin) stably expressed in mouse ZS cells using C6-NBD-ceramide as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by HPLC analysis2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
Malabaricone C as Natural Sphingomyelin Synthase Inhibitor against Diet-Induced Obesity and Its Lipid Metabolism in Mice.
AID337759Antimicrobial activity against Candida albicans 3110 after 48 hrs by agar dilution method
AID1497077Antidiabetic activity in rat L6 cells assessed as effect on 2-NBDG uptake at 50 uM pretreated for 24 hrs followed by 2-NBDG addition after 30 mins by FACS (Rvb = 20%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID337494Antimicrobial activity against Bacillus subtilis NCTC 10400 after 24 hrs by agar dilution method
AID1497078Antidiabetic activity in rat L6 cells assessed as increase in 2-NBDG uptake pretreated for 24 hrs followed by 2-NBDG addition after 30 mins by FACS2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID1308870Selectivity index, ratio of IC50 for equine serum BChE to IC50 for AChE (unknown origin)2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID1497070Inhibition of porcine pancreatic alpha-amylase using starch as substrate after 30 mins by iodine reagent based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID337495Antimicrobial activity against Streptococcus durans NCTC 8307 after 24 hrs by agar dilution method
AID1600503Inhibition of SMS1 (unknown origin) stably expressed in mouse ZS cells using C6-NBD-ceramide as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by HPLC analysis2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
Malabaricone C as Natural Sphingomyelin Synthase Inhibitor against Diet-Induced Obesity and Its Lipid Metabolism in Mice.
AID1467534Noncompetitive inhibition of Streptococcus pneumoniae sialidase NanC using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by Lineweaver-Burk plot/Dixon plot analysis2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1308871Selectivity index, ratio of IC50 for AChE (unknown origin) to IC50 for equine serum BChE2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID1308877Inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate incubated for 30 mins by Ellman's microplate assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID1497071Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate pretreated for 10 mins followed by substrate addition measured after 5 mins2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID337493Antimicrobial activity against Staphylococcus aureus NCTC 6571 after 24 hrs by agar dilution method
AID337496Antimicrobial activity against Candida albicans 3153 after 24 hrs by agar dilution method
AID337497Antimicrobial activity against Candida albicans 3110 after 24 hrs by agar dilution method
AID515751Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Comparative nuclease and anti-cancer properties of the naturally occurring malabaricones.
AID337756Antimicrobial activity against Bacillus subtilis NCTC 10400 after 48 hrs by agar dilution method
AID1467535Competitive inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by Lineweaver-Burk plot/Dixon plot analysis2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID337755Antimicrobial activity against Staphylococcus aureus NCTC 6571 after 48 hrs by agar dilution method
AID1600505Noncompetitive inhibition of SMS1 (unknown origin) stably expressed in mouse ZS cells using 5 to 50 uM C6-NBD-ceramide as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by HPLC analysis2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
Malabaricone C as Natural Sphingomyelin Synthase Inhibitor against Diet-Induced Obesity and Its Lipid Metabolism in Mice.
AID1497072Cytotoxicity against rat L6 cells up to 50 uM after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID1467532Noncompetitive inhibition of Streptococcus pneumoniae sialidase NanB using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by Lineweaver-Burk plot/Dixon plot analysis2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID337760Antimicrobial activity against Candida albicans ATCC 12301 after 48 hrs by agar dilution method
AID1497075Antidiabetic activity in rat L6 cells assessed as effect on 2-NBDG uptake at 10 uM pretreated for 24 hrs followed by 2-NBDG addition after 30 mins by FACS (Rvb = 20%)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID337757Antimicrobial activity against Streptococcus durans NCTC 8307 after 48 hrs by agar dilution method
AID1308869Inhibition of equine serum BChE using S-butyrylthiocholine chloride as substrate incubated for 30 mins by Ellman's microplate assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
AID1467529Inhibition of Streptococcus pneumoniae sialidase NanB using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1308872Mixed inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate incubated for 30 mins by Lineweaver-Burk plot analysis2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Natural cholinesterase inhibitors from Myristica cinnamomea King.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's9 (64.29)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.92 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetone
methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).		2.2510ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.4920alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
pyrogallol
benzenetriol : A triol in which three hydroxy groups are substituted onto a benzene ring.		2.1310benzenetriol;
phenolic donor		plant metabolite
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.7330aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		2.1710guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
myristicin
myristicin: asaricin is an isomer; structure; a methylene dioxy version of elemicin;		2.5420organic molecular entitymetabolite
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		2.7330aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		2.1310carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
acarbose
[no description available]		2.1710tetrasaccharide derivativeEC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent
2-deoxy-2,3-dehydro-n-acetylneuraminic acid
2-deoxy-2,3-dehydro-N-acetylneuraminic acid: also known as NeuAc2en, but this is also synonym for another compound. 2-deoxy-2,3-dehydro-N-acetylneuraminic acid : N-Acetylneuraminic acid reduced across the 2,3-bond with loss of the hydroxy group at C-2; it is a minor component of body fluids although abundant in sialuria.		2.1510N-acetylneuraminic acids
2-hydroxychavicol
2-hydroxychavicol: antimutagen from betel leaf; structure given in first source		2.0510
malabaricone c
malabaricone C: from maize (Myristica fragrans); structure given in first source		3.97120butanonemetabolite
4-allyl-2,6-dimethoxyphenol
4-allyl-2,6-dimethoxyphenol: structure in first source. 4-allyl-2,6-dimethoxyphenol : A member of the class of phenols that is phenol substituted by an allyl group at position 4 and methoxy groups at positions 2 and 6 respectively.		2.1510dimethoxybenzene;
phenols;
phenylpropanoid
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.1310
malabaricone a
malabaricone A: from Myristica malabarica (rampatri), has antipromastigote activity; structure in first source		3.3560
glycogen
glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.		2.0410
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.1310
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		2.1710aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0410prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
Licarin A
[no description available]		2.1510benzofurans
ginkgolic acid
[no description available]		2.2110hydroxybenzoic acid
surinamensin
surinamensin: RN given for (S-(R*,R*-(E)))-isomer; structure in first source		2.1310phenylpropanoid
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		2.0410
isoelemicin
isoelemicin: RN given refers to cpd without isomeric designation		2.1310olefinic compound
aldosterone
dehydrodiisoeugenol: an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages; structure in first source		2.5820
licarin b
licarin B: neolignan; RN given for (2S-(2alpha,3beta,5(E)))-isomer; isolated from seeds of Myristica fragrans; structure in first source		2.1310
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0510aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
verrucosin
verrucosin: disrupts ion homeostasis in the presence of acridine orange; isolated from Virola oleifera; structure in first source; do not confuse with either verrucosin A or verrucosin B		2.1510
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.1710
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.1710ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		02.1710
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.1710
Cancer of Lung
[description not available]		02.1710
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1710
Cancer of Prostate
[description not available]		02.1310
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1310
Gastric Ulcer
[description not available]		02.7330
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.7330
Black Fever
[description not available]		02.0310
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0410